By Elin Aslanyan
A Phase III study presented at the European League Against Rheumatism's (EULAR) 2015 Annual Scientific Meeting has promising results for secukinumab, an IL-17A inhibitor, in treating ankylosing spondylitis.
"Data from the study demonstrated that approximately 74% of patients achieved clinically significant improvement in their symptoms after one year of treatment, as measured by ASAS20, a standard tool used to assess clinical improvement in AS1. The safety and efficacy of investigational secukinumab are still under review for AS and market authorization has not been obtained."
"New data at one year show that improvements in the signs and symptoms of AS were sustained through 52 weeks of treatment."
Read the full press release: http://www.newswire.ca/en/story/1552883/novartis-announced-one-year-results-demonstrating-sustained-efficacy-with-investigational-secukinumab-in-ankylosing-spondylitis-patients-at-eular
What is IL-17A?
IL-17A (as well as IL-23 and subset p19, IL-6) are cytokines that play an important role in driving the immune response in inflammatory arthritic diseases, such as AS. Drugs like secukinumab work by interfering with the receptors of various immune cells and by this mechanism seek to reduce inflammation.
Cytokines play an important role in the inflammatory process; however when there is an overabundance of these, as has been described in inflammatory diseases, they can cause harm to the body if left unchecked.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.